{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:10:00Z","timestamp":1776406200679,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K1440403"],"award-info":[{"award-number":["23K1440403"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00228-026-04018-6","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:31:55Z","timestamp":1773815515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Creatinine- and cystatin C-based population pharmacokinetic models for predicting mycophenolic acid clearance in patients with autoimmune diseases"],"prefix":"10.1007","volume":"82","author":[{"given":"Shunsuke","family":"Nashimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Miyamae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"4018_CR1","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103\u20131112. https:\/\/doi.org\/10.1681\/ASN.2008101028","journal-title":"J Am Soc Nephrol"},{"key":"4018_CR2","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley MA, Jayne D, Ginzler EM et al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365:1886\u20131895. https:\/\/doi.org\/10.1056\/NEJMoa1014460","journal-title":"N Engl J Med"},{"key":"4018_CR3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/ndt\/gfu184","volume":"30","author":"T van Gelder","year":"2015","unstructured":"van Gelder T, Berden JH, Berger SP (2015) To TDM or not to TDM in lupus nephritis patients treated with MMF? Nephrol Dial Transpl 30:560\u2013564. https:\/\/doi.org\/10.1093\/ndt\/gfu184","journal-title":"Nephrol Dial Transpl"},{"key":"4018_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.clinthera.2008.04.014","volume":"30","author":"DR Kuypers","year":"2008","unstructured":"Kuypers DR, de Jonge H, Naesens M et al (2008) Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 30:673\u2013683. https:\/\/doi.org\/10.1016\/j.clinthera.2008.04.014","journal-title":"Clin Ther"},{"key":"4018_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RE Bullingham","year":"1998","unstructured":"Bullingham RE, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429\u2013455. https:\/\/doi.org\/10.2165\/00003088-199834060-00002","journal-title":"Clin Pharmacokinet"},{"key":"4018_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S0009-9236(98)90102-3","volume":"63","author":"HJ Johnson","year":"1998","unstructured":"Johnson HJ, Swan SK, Heim-Duthoy KL et al (1998) The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther 63:512\u2013518. https:\/\/doi.org\/10.1016\/S0009-9236(98)90102-3","journal-title":"Clin Pharmacol Ther"},{"key":"4018_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1592\/phco.29.1.7","volume":"29","author":"MS Joy","year":"2009","unstructured":"Joy MS, Hilliard T, Hu Y et al (2009) Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy 29:7\u201316. https:\/\/doi.org\/10.1592\/phco.29.1.7","journal-title":"Pharmacotherapy"},{"key":"4018_CR8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1681\/ASN.2005101070","volume":"17","author":"RM van Hest","year":"2006","unstructured":"van Hest RM, Mathot RA, Pescovitz MD et al (2006) Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 17:871\u2013880. https:\/\/doi.org\/10.1681\/ASN.2005101070","journal-title":"J Am Soc Nephrol"},{"key":"4018_CR9","doi-asserted-by":"publisher","first-page":"748609","DOI":"10.3389\/fphar.2021.748609","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Wu Y, Huang J et al (2021) Estimation of Mycophenolic Acid Exposure in Heart Transplant Recipients by Population Pharmacokinetic and Limited Sampling Strategies. Front Pharmacol 12:748609. https:\/\/doi.org\/10.3389\/fphar.2021.748609","journal-title":"Front Pharmacol"},{"key":"4018_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ki.1985.205","volume":"28","author":"O Shemesh","year":"1985","unstructured":"Shemesh O, Golbetz H, Kriss JP et al (1985) Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28:830\u2013838. https:\/\/doi.org\/10.1038\/ki.1985.205","journal-title":"Kidney Int"},{"key":"4018_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1042\/bj2680287","volume":"268","author":"M Abrahamson","year":"1990","unstructured":"Abrahamson M, Olafsson I, Palsdottir A et al (1990) Structure and expression of the human cystatin C gene. Biochem J 268:287\u2013294. https:\/\/doi.org\/10.1042\/bj2680287","journal-title":"Biochem J"},{"key":"4018_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/clinchem\/48.5.699","volume":"48","author":"OF Laterza","year":"2002","unstructured":"Laterza OF, Price CP, Scott MG (2002) Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48:699\u2013707. https:\/\/doi.org\/10.1093\/clinchem\/48.5.699","journal-title":"Clin Chem"},{"key":"4018_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/bdd.2383","volume":"45","author":"J Ling","year":"2024","unstructured":"Ling J, Yang X, Dong L et al (2024) Utility of cystatin C and serum creatinine-based glomerular filtration rate equations in predicting vancomycin clearance: A population pharmacokinetics analysis in elderly Chinese patients. Biopharm Drug Dispos 45:58\u201368. https:\/\/doi.org\/10.1002\/bdd.2383","journal-title":"Biopharm Drug Dispos"},{"key":"4018_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"key":"4018_CR15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M et al (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982\u2013992. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034","journal-title":"Am J Kidney Dis"},{"key":"4018_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1053\/j.ajkd.2012.07.007","volume":"61","author":"M Horio","year":"2013","unstructured":"Horio M, Imai E, Yasuda Y et al (2013) GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis 61:197\u2013203. https:\/\/doi.org\/10.1053\/j.ajkd.2012.07.007","journal-title":"Am J Kidney Dis"},{"key":"4018_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H et al (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367:20\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1114248","journal-title":"N Engl J Med"},{"key":"4018_CR18","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J et al (2021) New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med 385:1737\u20131749. https:\/\/doi.org\/10.1056\/NEJMoa2102953","journal-title":"N Engl J Med"},{"key":"4018_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40780-022-00271-w","volume":"9","author":"T Mizaki","year":"2023","unstructured":"Mizaki T, Nobata H, Banno S et al (2023) Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis. J Pharm Health Care Sci 9:1. https:\/\/doi.org\/10.1186\/s40780-022-00271-w","journal-title":"J Pharm Health Care Sci"},{"key":"4018_CR20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s13318-017-0420-3","volume":"42","author":"AN Abd Rahman","year":"2017","unstructured":"Abd Rahman AN, Tett SE, Abdul Gafor HA et al (2017) Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis. Eur J Drug Metab Pharmacokinet 42:993\u20131004. https:\/\/doi.org\/10.1007\/s13318-017-0420-3","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"4018_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.5414\/cp201605","volume":"50","author":"B Punyawudho","year":"2012","unstructured":"Punyawudho B, Lertdumrongluk P, Somparn P et al (2012) Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients. Int J Clin Pharmacol Ther 50:272\u2013280. https:\/\/doi.org\/10.5414\/cp201605","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4018_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1177\/0961203320931567","volume":"29","author":"M Romano-Aguilar","year":"2020","unstructured":"Romano-Aguilar M, Res\u00e9ndiz-Galv\u00e1n JE, Medell\u00edn-Garibay SE et al (2020) Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. Lupus 29:1067\u20131077. https:\/\/doi.org\/10.1177\/0961203320931567","journal-title":"Lupus"},{"key":"4018_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bcp.2007.03.024","volume":"74","author":"Y Uwai","year":"2007","unstructured":"Uwai Y, Motohashi H, Tsuji Y et al (2007) Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol 74:161\u2013168. https:\/\/doi.org\/10.1016\/j.bcp.2007.03.024","journal-title":"Biochem Pharmacol"},{"key":"4018_CR24","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00228-021-03265-z","volume":"78","author":"Z Li","year":"2022","unstructured":"Li Z, Huang Y, Xu H et al (2022) Population pharmacokinetic and dose optimization of mycophenolic acid in children with anti-neutrophilic cytoplasmic antibody-associated nephritis. Eur J Clin Pharmacol 78:831\u2013838. https:\/\/doi.org\/10.1007\/s00228-021-03265-z","journal-title":"Eur J Clin Pharmacol"},{"key":"4018_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1373\/49.4.680","volume":"49","author":"V Jayagopal","year":"2003","unstructured":"Jayagopal V, Keevil BG, Atkin SL et al (2003) Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. Clin Chem 49:680\u2013681. https:\/\/doi.org\/10.1373\/49.4.680","journal-title":"Clin Chem"},{"key":"4018_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/s0009-8981(00)00298-9","volume":"300","author":"N Cimerman","year":"2000","unstructured":"Cimerman N, Brguljan PM, Krasovec M et al (2000) Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta 300:83\u201395. https:\/\/doi.org\/10.1016\/s0009-8981(00)00298-9","journal-title":"Clin Chim Acta"},{"key":"4018_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000057599","volume":"91","author":"JJ Kazama","year":"2002","unstructured":"Kazama JJ, Kutsuwada K, Ataka K et al (2002) Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Nephron 91:13\u201320. https:\/\/doi.org\/10.1159\/000057599","journal-title":"Nephron"},{"key":"4018_CR28","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1046\/j.1523-1755.2002.00531.x","volume":"62","author":"D Cattaneo","year":"2002","unstructured":"Cattaneo D, Perico N, Gaspari F et al (2002) Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 62:1060\u20131067. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00531.x","journal-title":"Kidney Int"},{"key":"4018_CR29","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/s0041-1345(98)01936-8","volume":"31","author":"M Shipkova","year":"1999","unstructured":"Shipkova M, Sch\u00fctz E, Armstrong VW et al (1999) Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transpl Proc 31:1135\u20131137. https:\/\/doi.org\/10.1016\/s0041-1345(98)01936-8","journal-title":"Transpl Proc"},{"key":"4018_CR30","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/s0041-1345(98)00201-2","volume":"30","author":"E Sch\u00fctz","year":"1998","unstructured":"Sch\u00fctz E, Shipkova M, Armstrong VW et al (1998) Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transpl Proc 30:1185\u20131187. https:\/\/doi.org\/10.1016\/s0041-1345(98)00201-2","journal-title":"Transpl Proc"},{"key":"4018_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clpt.2005.03.004","volume":"78","author":"DR Kuypers","year":"2005","unstructured":"Kuypers DR, Verleden G, Naesens M et al (2005) Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther 78:81\u201388. https:\/\/doi.org\/10.1016\/j.clpt.2005.03.004","journal-title":"Clin Pharmacol Ther"},{"key":"4018_CR32","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1093\/ndt\/gfp162","volume":"24","author":"JM Griny\u00f3","year":"2009","unstructured":"Griny\u00f3 JM, Ekberg H, Mamelok RD et al (2009) The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transpl 24:2269\u20132276. https:\/\/doi.org\/10.1093\/ndt\/gfp162","journal-title":"Nephrol Dial Transpl"},{"key":"4018_CR33","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1111\/j.1600-6143.2009.02682.x","volume":"9","author":"S Kofler","year":"2009","unstructured":"Kofler S, Shvets N, Bigdeli AK et al (2009) Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transpl 9:1650\u20131656. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02682.x","journal-title":"Am J Transpl"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04018-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04018-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04018-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:37:32Z","timestamp":1776404252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04018-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4018"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04018-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and its amendments. The study protocol was approved by the Ethical Review Board for Life Science and Medical Research of Hokkaido University Hospital (Protocol number: 024\u20130254).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}